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A B S T R A C T
Phenobarbital and primidone frequently have adverse effects onmental functions. Therefore, an attempt
was made to taper barbiturates in 85 patients out of a resident population with epilepsy and intellectual
disability who were selected according to clinical criteria. The objectives were to reduce the use of
barbiturates, to improve the patients’ cognitive and psychological state, and to reduce polypharmacy
while avoiding seizure exacerbation. Four months after complete withdrawal changes in seizure
frequency were assessed as well as changes in cognitive abilities, psychological state and behaviour
(using the clinical global impression scale). In 13 patients the tapering failed due to complications
(seizure increase in 11 patients). In 72 patients the barbiturate was completely withdrawn (mean
duration of tapering: 393 days). Cognitive improvement was achieved in 17 patients (23.6%), 5 patients
(6.9%) deteriorated. Seizure frequency remained unchanged in 33 patients (45.8%), in another 15 patients
(20.8%) the seizure frequency decreased. Reduction in polypharmacywas obtained in 61 patients (84.7%).
In an overall judgement (clinical global impression scale) of cognitive abilities AND seizure control, 25
patients (34.7%) were improved. 31 patients (43.1%) remained unchanged while 12 patients deteriorated
(4 patients: impossible to judge). For statistical analysis three outcome groups were deﬁned: the
improved group (N = 25), the unchanged group (N = 31), and the deteriorated/failed group (N = 25)
consisting of the 12 deteriorated patients plus the 13 patients in whom tapering failed. Stepwise logistic
regression revealed a history of an attempt towithdraw phenobarbital/primidone (p = 0.017; OR 3.8), age
(p = 0.012) and seizure frequency (marginally signiﬁcant: p = 0.097) as outcome predictors. Older agewas
associated with better outcome. A high seizure frequency before tapering was related to good outcome,
while seizure freedom and a history of failed withdrawal were associated with deterioration/failure.
Outcome did not depend on duration of barbiturate therapy, dosage or serum concentration, co-
medication, reduction rate, degree of intellectual disability, or epilepsy syndrome. In summary, the
number of barbituratemedications has been considerably reduced, but the principal aim of the project, to
relieve patients from assumed barbiturate side effects, has been achieved only in one out of four patients.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Phenobarbital (PB) is, apart from the bromides, the oldest
modern antiepileptic drug (AED). Primidone (PRM) is another
barbiturate, which is rapidly metabolised to phenobarbital. Both
the barbiturates are known to be highly effective but they are also
notorious for their side effects. Two recent cochrane reviews come
to the conclusion that PB is less well tolerated than the other* Corresponding author. Tel.: +49 521 144 2829; fax: +49 521 144 4736.
E-mail address: Bernd.Huber@Bethel.de (B. Huber).
1 Society for Epilepsy Research.
1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.07.006classical AED CBZ2.1,2 Sedation and listlessness, irritability and
hyperactivity, exacerbation of aggressiveness, depression, and
impairment of memory and concentration are among the potential
adverse effects on mental functioning.3 Learning difﬁculties and
other unwanted effects on cognition, attention and mood have
been described especially in children.4–11 Similar effects are
frequently seen in patients with intellectual disability12,13
although hard evidence is lacking. Recent research has shed some2 Abbreviations of AEDs: CBZ: carbamazepine; ESM: ethosuximide; LTG:
lamotrigine; OCBZ: oxcarbazepine; PB: Phenobarbital; PHT: phenytoin; PRM:
primidone; TPM: topiramate; VPA: valproic acid/sodium valproate.
vier Ltd. All rights reserved.
Fig. 1. Overview.
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latencies (auditory event-related potentials, ameasure of cognitive
functions like decision-making, stimulus processing and memory)
were found to be delayed in seizure free children on monotherapy
with PB but not with CBZ or VPA.14 As a consequence of these
disadvantages, the use of barbiturates declined over the years as
was shown in several studies on the long-term course of epilepsy
and epilepsy treatment.15–18 According to most clinicians,
barbiturates are no longer a treatment of ﬁrst choice, especially
not in children and in patients with intellectual disability.12,13,19,20
On theotherhand, PBhas also someadvantages: It is effective ina
broad spectrum of focal as well as generalised epilepsy syndromes
(but not in classical absences). Its long half life can be favourable in
patientswho tend tomissmedicationdoses.And lastbutnot least, in
a more global perspective, the low prize makes it affordable even in
parts of the world with limited resources.21,22 An excellent
delineation of the pros and cons of PB is given by Kwan.23
In our organisation, which has a long tradition in epilepsy
treatment, PB (and to a less extent PRM) has been broadly used for
decades. When newer AEDs became available (CBZ and VPA since
the sixties, several new AEDs since the nineties of the last century),
the use of the barbiturates gradually abated. Nevertheless, an
investigation in antiepileptic therapy regimens in our organisation
carried out in 2002 revealed that as many as 229 resident patients
(33.9%) were being treated with PB or PRM (alone or in
combination with other AEDs). This rate seemed relatively high,
also in comparison with data from other organisations.24–26
Therefore, we started an attempt to withdraw barbiturates in
our resident population; this paper reports the experience made.
This project had the following objectives: To reduce the use of
barbiturates; to improve the patients’ cognitive and psychological
state by eliminating supposed PB side effects; to avoid seizure
exacerbation (or even achieve seizure decrease) and other
complications; to reduce polypharmacy.
2. Patients and methods
In 2004 we reviewed the 229 patients who had been on
barbiturate therapy in 2002. Thirteen patients had died and 3 had
left our organisation. One patient could not be reviewed for an
individual reason. Twenty-one patients were no longer on PB.
Thus, 191 patients on barbiturate therapy (184 on PB, 7 on PRM)
were left in 2004.
A thorough individual case evaluation was undertaken on all of
these 191 patients by the ﬁrst author together with the staff
neurologist or psychiatrist in charge for the individual patient. The
individual medical case records (which are voluminous in many
cases) were carefully studied. Present and past seizure records
were evaluated as well as notes on effects and side effects of all
antiepileptic drugs administered. A synopsis on AED dosages and
serum concentrations back to 1977, provided by the antiepileptic
drug laboratory, was also used to get an overview over treatment
history. Important questions and considerations in the evaluation
process included: The duration of PB treatment; information on
effects when PB had been started; outcome of earlier attempts to
taper PB; availability of alternative therapeutic options; interac-
tions between PB and concomitant medication. An estimation of
the risk of seizure relapse or increase was made using all available
information on seizure frequency in earlier years, course of earlier
medication changes, and effect when PB was initially added to the
patient’s regimen. The potential consequences of a possible seizure
relapse or increase for the respective patient were also considered.
Special caution was applied in seizure free patients27 and in the
elderly above 70 years of age. Finally, the ﬁrst author together with
the staff neurologist/psychiatrist in charge came to an individualdecision whether to maintain or to taper PB/PRM. This decision
comprehended all relevant medical aspects and also the patients’
whole life situation. For the group designed to taper PB/PRM, the
ﬁrst author and the staff neurologist/psychiatrist in charge also
deﬁned an individual stepwise reduction pattern for each patient
according to his or her medical and personal circumstances.
Possible reasons for slow tapering were, among others: patient
known to be prone to seizure increase on medication change;
history of seizure-related falls, danger of bone fractures. Possible
reasons for a faster tapering included: lack of initial PB efﬁcacy; no
increased risk of status epilepticus, falls or fractures. PB was then
reduced step by step by the neurologist/psychiatrist in charge, who
held regular clinics (approx. biweekly to once in 6 weeks) with the
patients and their immediate care-takers. When problems arose,
they were discussed between the physician in charge and the ﬁrst
author. The original reduction pattern was revised when required.
Adaptations of the concomitant medication were made when
clinically necessary. Patients lived their normal lives during the
tapering procedure (most of themworked in a sheltered workshop
or attended a senior persons’ day centre).
Four months after complete PB withdrawal a post-evaluation
wasmade.Whenmedication adjustmentswere still ongoing or the
seizure frequency was not yet clear after 4 months the ﬁrst author
could extent this period to 6 months.
For the assessment of changes in cognitive abilities, psycho-
logical status and behaviour the clinical global impression scale
(CGI) was applied.28 The questionnaire was ﬁlled in by the staff
neurologist/psychiatrist, after consultation with the care-takers
and, where possible, with the patient. The slightly adapted tool
included the following questions: ‘‘Is the patient impaired (with
respect to cognition/psychological state/behaviour) by his/her
antiepileptic medication?’’ (to be answered before and after
withdrawal) ‘‘Are there any changes in cognition/psychological
state/behaviour?’’ An overall judgement: ‘‘What is the overall
clinical effect of the intervention, also considering possible
changes in seizure frequency or severity?’’ (to be answered after
withdrawal)
Statistical analysis (Fisher’s exact test, one-sided; Kruskal–
Wallis test) was performed by one of the authors (T.M.) using SPSS
version 15.
3. Results
The clinical decision achieved as described above was to
maintain the barbiturate (PRM: 1 patient) in 93 persons (the
Table 1
Patient characteristics of the different groups
Maintenance group (N = 93) Withdrawal group (N = 72) Tapering failed group (N = 13) Exclusions (N = 13)
Male:female 44:49 43:29 10:3 6:7
PB dose (before tapering) in mg/d 129.1  61.8 127.6  61.9 150.4  86.4 112.3  60.3
PB concentration (mg/ml) 22.0  9.7 24.4  9.5 30.6  13.0 22.5  8.3
Age group
18–29 3 (3.2%) 6 (8.3%) 2 (15.4%) 1 (<18) (7.7%)
30–39 2 (2.2%) 13 (18.1%) 4 (30.8%) 2 (15.4%)
40–49 6 (6.5%) 13 (18.1%) 2 (15.4%) 1 (7.7%)
50–59 13 (14.0%) 17 (23.6%) 3 (23.1%) 1 (7.7%)
60–69 39 (41.9%) 20 (27.8%) 2 (15.4%) 6 (46.2%)
70–79 21 (22.6%) 3 (4.2%) – 2 (15.4%)
80–89 9 (9.7%) – – –
Epilepsy syndrome
Symptomatic/cryptogenic focal 53 (57.0%) 41 (56.9%) 6 (46.2%) 7 (53.8%)
Symptomatic/cryptogenic multifocal 1 (1.1%) 7 (9.7%) 1 (7.7%) 1 (7.7%)
Symptomatic/cryptogenic generalized 14 (15.1%) 5 (6.9%) 1 (7.7%)
Idiopathic generalised 6 (6.5%) – 1 (7.7%) –
With focal and generalised seizures 16 (17.2%) 11 (15.3%) 3 3 (23.1%)
Lennox–Gastaut syndrome – 5 (6.9%) – 1 (7.7%)
Progressive myoclonic epilepsy – – 1 (7.7%) –
Unclassiﬁed 3 (3.2%) 3 (4.2%) 1 (7.7%) –
Sz frequency (before tapering)
Completely seizure free 67 (72.0%) 8 (11.1%) 4 (30.1%) 2 (15.4%)
Nearly seizure freea 8 (8.6%) 1 (1.4%) – 2 (15.4%)
>1/year 11 (11.8%) 22 (30.6%) 1 (7.7%) 2 (15.4%)
>1/month 5 (5.4%) 25 (34.7%) 6 (46.2%) 6 (46.2%)
>1/week 2 (2.2%) 14 (19.4%) 2 (15.4%) 1 (7.7%)
>1/day – 2 (2.8%) – –
Intellectual disability
None 10 (10.8%) 1 (1.4%) 1 (7.7%) 1 (7.7%)
Borderline intelligence 6 (6.5%) 4 (5.6%) 1 (7.7%) 1 (7.7%)
Mild 26 (28.0%) 17 (23.6%) 3 (23.1%) 5 (38.5%)
Moderate 29 (31.2%) 22 (30.6) 4 (30.1%) 3 (23.1%)
Severe 19 (20.4%) 23 (31.9%) 4 (30.1%) 2 (15.4%)
Profound 2 (2.2%) 5 (6.9%) – 1 (7.7%)
Missing data 1 (1.1%) – – –
CGI before tapering
Not at all impaired 19 (26.4%) 3 (23.1%) 2 (15.4%)
Suspected of being impaired 8 (11.1%) 5 (38.5%) 2 (15.4%)
Slightly impaired 1 (1.4%) – –
Clearly impaired 2 (2.8%) – –
Impossible to judge 42 (58.3%) 5 (38.5%) 9 (69.2%)
a This was compatible with 1–2 seizures/year due to acute disease, forgotten medication, etc.
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patients are given in Table 1. The reasons for maintaining PB are
given in Table 2.
In 98 patients the decision was to taper the barbiturate (PRM:
6). However, 13 of these patients (2 on PRM) had to be excluded
for a variety of reasons: 5 patients and 1 legal representative
disagreed tapering for fear of complications. In 2 cases a series
of medical complications unrelated to epilepsy delayed the
tapering very much or rendered it impossible. Another patient
underwent epilepsy surgery with promising results and, there-
fore, tapering was not carried out. Two seizure free patients
(one on PB monotherapy) had to be taken out of the evaluation
due to an extremely slow withdrawal schedule (e.g., 15 mg/3–6
months). Two patients died during the trial, both obviously
unrelated to epilepsy or antiepileptic treatment.3 See Table 1
for characteristics of the excluded patients. The remaining
85 patients (PRM: 4) will be referred to as the taper group
(Fig. 1).3 A severely handicapped 69-year-old man suffering from neuroﬁbromatosis
died in the context of respiratory infection; a severely handicapped 66 year old
woman who had colon carcinoma died from pneumonia.In 13 patients (PRM: 2) of the taper group, the tapering had to be
aborted (12 patients) or reversed (PB re-introduced; one patient)
due to complications (Table 1, tapering failed group; Fig. 1).
In 72 patients the barbiturate (PRM: 2) was completely
withdrawn (the withdrawal group; Table 1 and Fig. 1).
3.1. The taper group (N = 85)
The reasons given for the tapering decision are shown in
Table 3.
The duration of barbiturate therapy was considerably long in
most of the patients: 63 patients (74%) had been on a barbiturate
for more than 20 years (<5 years: 3 patients; 6–10 years: 4; 11–15
years: 7; 16–20 years: 8). Twenty-three patients had experienced
earlier attempts to withdraw the barbiturate drug; these earlier
attempts usually dated back formany years or had been carried out
in the context of a different co-medication.
Before the tapering started the patients had PB dosages of
131  66 mg/d (mean value  standard deviation;median 115 mg/d;
range 30–400 mg/d) and serum concentrations of 25.3  10.2 mg/ml
(x  S.D.; median 24.2; range 4.7–59 mg/ml). The maximum PB
dosage in history was 213.5  96.1 mg/d (x  S.D.; median 200 mg/d;
Table 2
Reasons given for maintaining PB/PRM (N = 93)
Reason N
Seizure freedom 57
PB sole AED 20
Old age 19
No side effects 15
Take no risk 14
PB/PRM efﬁcacy proven 11
Seizures rare/mild 11
Increased relapse risk 10
Severe co-morbidity/multi-morbidity 8
Patient wish 8
PB/PRM withdrawal failed in history 7
Low dosage/serum concentration 5
Long half life (irregular medication intake) 4
Four other reasons 6
In most patients a combination of reasons was given.
Table 3
Reasons given for tapering PB/PRM (n = 98a)
Reason N
Simplify combination therapy 40
Insufﬁcient seizure control 33
PB efﬁcacy unclear or doubtful 30
Adverse interaction (e.g., with psychotropics), enzyme induction 17
Side effects 17
Alternative therapy options 14
Low risk of seizure exacerbation 12
Very long lasting seizure freedom 9
Rare or bland seizures 3
Five other reasons 8
More than one reason per patient could be given.
a Taper group (n = 85) + 13 patients in whom tapering was planned but could not
carried out; see text.
4 The improved group includes two patients who had a slight seizure increase
which was far outweighed by cognitive improvement, resulting in a positive CGI
overall judgement. Vice versa, one patient (E.W. in Table 8) in the improved group
was more verbally aggressive after PB withdrawal. As this happened only
sometimes and could be managed by her environment it was thought to be minor
seeing her seizure reduction. Therefore, the CGI overall judgement was positive.
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of maximum PB serum concentrations in history. Some of the
maximum PB serum concentrations in history were extremely high.
These values usuallywere the ﬁrst serum level determined ever in the
individual patients in the late-1970 years, shortly after this method
had become available; barbiturate dosages usually were reduced
subsequently.
The mean long-run PB daily dosage (dosage maintained over
the longest period of time in history)was 135  57.8 mg/d (x  S.D.;
median 130 mg/d, range 45–375 mg/d). For the distribution of long-
term PB serum concentrations see Fig. 2 (grey columns).
The 4 patients on PRM had maximum dosages in history from
625 to 750 mg/d and long-run dosages from 187.5 to 625 mg/d.
Forty-one patients had one antiepileptic co-medication, 32
patients had two, 4 had three, and 2 patients had four antiepileptic
drugs apart from the barbiturate. Six patients were on PB
monotherapy. The most frequent therapy regimens were PB/
PRM + CBZ (20 patients), PB + LTG/VPA (12), PB + OCBZ (9),
PB + PHT (5), PB + VPA (4); a number of other combinations
occurred in less than 3 patients.
As mentioned above, for each patient an individual reduction
pattern was determined (Table 4). In many cases, however, the
designed patterns could not exactly be adhered to. Delays resulted
from complications of the tapering itself but were also due to
independent medical conditions and personal circumstances. The
actual reduction rate per 30 days was 14.1  12.8 mg/d (x  S.D.;
range 1.9–62.5 mg/d). The reduction rate in serum concentration was
3.1  3.8 mg/ml per 30 days (x  S.D.; range 0.3–28.7 mg/ml). In those
successfully withdrawn, the duration of the tapering procedure was
393  266 days (x  S.D.; range: 1–1330 days)3.2. The withdrawal group (N = 72)
Of the 72 patients in whom PB/PRM was successfully with-
drawn, polypharmacy (=number of AEDs prescribed per patient)
was reduced in 61 patients. In the remaining 11 patients another
AED had to be introduced instead of PB and, therefore, no reduction
of polytherapy was achieved.
The results of the assessment of changes secondary to PB
withdrawal are summarized in Tables 5–7. Before the tapering, it
was impossible in a majority of the patients to knowwhether they
were impaired by their barbiturate medication. After withdrawal
68% of the patients were assessed as not being impaired by their
remaining medication (Table 5).
An improvement in cognition, psychological state and/or
behaviour attributed to withdrawal of PB occurred in 17 patients
(23.6%) while no changewas observed in 44 patients (61.1%), and 5
patients (6.9%) deteriorated (Table 6). 15 patients (20.8%) had a
reduction in seizure frequency of different degree, 20 patients
(27.8%) experienced an increase in seizures, while seizure
frequency remained unchanged in 33 (45.8%; Table 6). The overall
judgement (CGI) of the intervention showed an improvement of
different degree in 25 patients (34.7%) while 31 patients (43.1%)
remained unchanged and 12 (16.7%) worsened (Table 6).
An overview over the relation between cognitive/psychological
changes, seizure frequency and overall judgement (CGI) is shown
in Table 7.
3.3. Changes in the concomitant medication (withdrawal group,
N = 72)
The most frequent concomitant medications were CBZ (26
patients), VPA (23 patients), LTG (19), OCBZ (12) and PHT (8).
A great number of changes in co-medication happened. A
considerable part of them was subsequent to PB pharmacokinetic
interactions. In 24 patients the serum concentration of concomi-
tant AED(s) increased (not caused by dosage change of that AED)
due to the elimination of PB-related enzyme induction. While this
led to toxicity in some cases, it improved seizure control in others.
In 15 patients, the dosage of a concomitant AED had to be adjusted
in order to keep the serum concentration stable (as a compensation
for serum level changes caused by omission of interactionwith PB).
Other changes independent of pharmacokinetic PB interactions
were intended to improve seizure control in compensation for PB
withdrawal. They included dosage increases in 15 patients and
reductions in 11 patients. In 24 patients an AED was added to the
medication (VPA and OCBZ 9 cases each, LTG 5 cases), and in 13
patients an AED (apart from PB) was discontinued (in 11 patients
the discontinued AEDwas replacedwith another AED; in 4 of these
cases CBZ was replaced with OCBZ).
Co-medication remained unchanged in only 9 patients.
3.4. Improved patients
Twenty-ﬁve patients (34.7%) showed clinical improvement on
PB withdrawal (Table 7, slight/clear/comprehensive improve-
ment). 12 of them experienced a decrease in seizure frequency,
15 were cognitively improved (Table 7, columns with grey
background).4 Details of these patients are summarized in Table 8.
Fig. 2. PB serum concentrations in history (N = 85, the taper group). *15: around 15 = 12.5–17.5; *20: around 20 = 17.5–22.5: around 25: 22.5–27.5mg/ml, etc. Grey/striped
columns: long-run/maximum PB serum concentration in history.
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3.5.1. Temporary problems
Temporary problems, mostly but not exclusively withdrawal
seizures, occurred in 33 of the 72 (45.8%) patients who
discontinued PB (Table 9).
3.5.2. Lasting deterioration
Twenty-one patients deteriorated on PB withdrawal (CGI
overall judgement), in most cases due to seizure increase but
psychiatric/behavioural problems also occurred. For clinical details
see Table 10.Table 4
Individual reduction patterns as planned (taper group, N = 85)
Reduction pattern mg/d per 30 daysa N
50 mg/4 weeks 53.6 2
25 mg/4 weeks 26.8 15
25 mg/6 weeks 17.9 2
50 mg/3 months 16.7 1
15 mg/4 weeks 16.1 17
25 mg/8 weeks 13.4 8
15 mg/6 weeks 10.7 1
25 mg/3 months 8.3 4
15 mg/8 weeks 8.0 5
15 mg/3 months 5.0 4
50 mg in 1 step 1
Not speciﬁed/dependent on clinical course 23
In 4 patients on PRM, a reduction of 62.4 mg/4weekswas scheduled in one, 125 mg/
4 weeks in the other (1: not speciﬁed; 1: ﬁrst changed to PB, then 15 mg/3months).
a In order to make the different patterns easier to compare, they were converted
in mg/d per 30 days.
Table 5
CGI before and after barbiturate withdrawal (withdrawal group, N = 72) (‘‘Is the
patient impaired by his/her antiepileptic medication?’’)
CGI before N (%) CGI after N (%)
Not at all impaired 19 (26.4%) 49 (68.1%)
Suspected of being impaired 8 (11.1%) 0
Slightly impaired 1 (1.4%) 1 (1.4%)
Clearly impaired 2 (2.8%) 1 (1.4%)
Impossible to judge 42 (58.3%) 21 (29.2%)
CGI: clinical global impression scale.3.6. Patients in whom PB tapering failed (N = 13)
Table 11 discloses details on the clinical course of the 13
patients in whom PB tapering failed due to seizure increase and/or
other complications.
3.7. The outcome groups
For the purpose of statistical analysis we categorized the
patients in three main outcome groups: The improved group (N = 25): slight/clear/comprehensive in CGI
overall judgement (Table 7, columns with grey background) The unchanged group (N = 31); CGI overall judgement:
unchanged (Table 7, column ‘‘unchanged’’). Most of these
patients remained completely unchanged despite PB disconti-
nuation. In a few patients of this group results were contra-
dictory or ambiguous (e.g., more seizures but better mood)
resulting in an ‘‘unchanged’’ overall judgement. The deteriorated/failed group (N = 25) comprises the patients
who clinically deteriorated on PB withdrawal (N = 12; Table 7,
column ‘‘worse’’) PLUS the patients in whom PB tapering had to
be aborted/reversed (N = 13; Table 11).
3.8. Statistical analysis
Univariate statistical analysis indicated that outcome was
signiﬁcantly dependent on seizure frequency, age, earlier attempts
of PB/PRM withdrawal and co-medication with CBZ or VPA. A high
seizure frequency before tapering was related to good outcome
(improvement), while seizure freedom was associated with
deterioration/failure (p = 0.036). Older age was also associated with
better outcome (p = 0.017), whereas a history of earlier attempts to
withdraw PB/PRM was a strong predictor for deterioration/failure
(p = 0.009). In terms of co-medication, outcome depended on the
presence of CBZ (which was associated with improvement;
p = 0.026) and VPA (which was associated with deterioration/
failure; p = 0.028), but not on the presence of LTG, OCBZ or PHT.
No relationship was found between outcome and epilepsy
syndrome, degree of intellectual disability, number of concomitant
AEDs, duration of barbiturate therapy, maximum dosage or serum
Table 6
Changes after complete barbiturate withdrawal (withdrawal group N = 72)
Change in cognition. . .? (CGI) N (%) Seizure frequency N (%) Effect of intervention, overall judgement (CGI) N (%)
Very much improved 1 (1.4%) >50% Sz reduction 9/12.5% Very good effect; comprehensive improvement 2 (2.8%)
Much improved 8 (11.1%) 25–50% Sz reduction 5/6.9% Moderate effect; clear improvement 12 (16.7%)
Slightly improved 8 (11.1%) Sz reduction (not quantiﬁable) 1/1.4% Small effect; slight improvement 11 (15.3%)
Unchanged 44 (61.1%) Unchanged 28/38.9% Unchanged 31 (43.1%)
Slightly worse 4 (5.5%) Remained Sz free 5/6.9% Worse 12 (16.7%)
Much worse 1 (1.4%) Sz relapse (Sz free before) 3/4.2% Impossible to judge 4 (5.5%)
Impossible to judge 6 (8.3%) 25–50% Sz increase 4/5.6%
>50% Sz increase 11/15.3%
Sz increase (not quantiﬁable) 2/2.8%
Impossible to judge 4/5.6%
Cognition. . .: cognition/psychological state/behaviour; Sz: seizure. CGI: clinical global impression scale. In 10 patients who had more seizures the increase was rated as
‘‘impairing’’.
Table 7
Changes in cognition/psychological state/behaviour and in seizure frequency differentiated by CGI overall judgement (withdrawal group N = 72)
CGI overall Comprehensive improvement Clear improvement Slight improvement Unchanged Worse Impossible to judge Sum
Cognition. . .
Very much improved – 1 (9.1%) – 1 (1.4%)
Much improved 2 (100%) 5 (41.7%) 1 (3.2%) – 8 (11.1%)
Slightly improved 2 (16.7%) 5 (45.5%) 1 (8.3%) – 8 (11.1%)
Unchanged 5 (41.7%) 4 (36.4%) 27 (87.1%) 6 (50%) 2 (50%) 44 (61.1%)
Slightly worse 1 (9.1%) 3 (25%) 4 (5.5%)
Much worse – 1 (8.3%) – 1 (1.4%)
Impossible to judge 3 (9.7%) 1 (8.3%) 2 (50%) 6 (8.3%)
Sum 2 (100%) 12 (100%) 11 (100%) 31 (100%) 12 (100%) 4 (100%) 72 (100%)
Sz frequency
Seizure reductiona – 7 (58.3%) 5 (45.5%) 3 (9.7%) – – 15 (20.8%)
Unchangedb 2 (100%) 5 (41.7%) 4 (36.4%) 20 (64.5%) 1 (8.3%) 1 (25%) 33 (45.8%)
Seizure increasec – – 2 (18.2%) 7 (22.6%) 10 (83.3%) 1 (25%) 20 (27.8%)
Impossible to judge – – – 1 (3.2%) 1 (8.3%) 2 (50%) 4 (5.6%)
Sum 2 (100%) 12 (100%) 11 (100%) 31 (100%) 12 (100%) 4 (100%) 72 (100%)
a Seizure reduction: includes Table 6 classes ‘‘>50% seizure reduction’’, ‘‘25–50% seizure reduction’’ and ‘‘Seizure reduction (not quantiﬁable)’’.
b Includes Table 6 classes ‘‘Unchanged’’ and ‘‘Remained seizure free’’.
c Includes Table 6 classes ‘‘Seizure relapse (seizure free before)’’, ‘‘25–50% seizure increase’’ ‘‘>50% seizure increase’’ and ‘‘Seizure increase (not quantiﬁable)’’.
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reduction rate (dosage, serum concentration) in univariate
statistical analysis.
Stepwise logistic regression revealed a history of an attempt to
withdraw PB/PRM (p = 0.017; OR 3.8; CI 1.3–11.2), age (p = 0.012)
and seizure frequency (only marginally signiﬁcant: p = 0.097) as
outcome predictors. CBZ or VPA were no longer signiﬁcant
(p > 0.1) when the predictors mentioned before were included
in the logistic regression equation.
3.9. Seizure free patients
Of the 13 previously seizure free patients, the tapering had to be
abandoned in 4 due to seizure recurrence. In 9 patients PB/PRMwas
completelywithdrawn,4of themexperienced seizures again.Only5
patients remained seizure free. Only 1 patient had an improvement
in her cognitive/psychological state (Table 8, patient E.G.).
3.10. Patients on PB monotherapy
Six patients were on PB monotherapy. In 2 of them the tapering
had to be abandoned (C.T.; U.D., Table 11). In 3 patients PB was
replacedwith another AED (CBZ, OCBZ, VPA). Two of these patients
experienced improvement of their psychological state, none of
them showed a signiﬁcant change in seizure frequency. One
patient remained seizure free after his antiepileptic medication
was completely discontinued.4. Discussion
There is a history of barbituratewithdrawal trials.4,16,29–37Most
of themwere conducted before an increasing number of new AEDs
became available in the 1990 years. Sometimes, other sedative
AEDs besides barbiturates were also withdrawn, or barbiturate
withdrawal occurred as part of a program to rationalise and reduce
existing polypharmacy.30–34,37 In some of the trials, case numbers
were low.30–32,36 Most of the publications pointed out that it was
possible to reduce the use of barbiturates without seizure
increase16,31,33–36 but difﬁculties or failure to withdraw PB were
also mentioned.32–34,37 Favourable effects on behaviour and
cognition secondary to barbiturate removal were described4,34,36
but in some work they were limited to a small number of
patients.16,33 Occasionally, authors tended to downplay difﬁculties
and complications of the withdrawal procedure.
Our paper, which includes a relatively large number of patients,
is one of few reports on barbiturate withdrawal in the era of the
new AEDs. We have tried to draw a realistic picture of the
achievements for individual patients but also of the multitude of
problems that emerged. We are aware of some methodological
limitations of our work. The reported changes in cognition,
behaviour and mood mentioned are not based on formal
neuropsychological testing, but on a relatively gross instrument,
the CGI scale, and on clinical descriptions. On the other hand, this
tool has the advantage to be applicable in patients with all degrees
of intellectual impairment. The clinical descriptions, provided by
Table 8
Improved patients (N = 25)
Patient initials/sex Age group Intellectual disability Details of clinical improvement
Clear or very good improvement
M.K./F 40–49 Moderate Less slowed, more mobile
E.G./F 30–39 Mild More alert, more interested
M.M./M 40–49 Severe Behaviour improved, less stereotypies, more alert
H.T./M 60–69 Moderate Less seizures
R.S./F 60–69 Moderate Became seizure free
C.S./F 30–39 Moderate Approx. 50% seizure reduction
E.D./F 50–59 Mild Substantially less slowed; more ‘‘normal’’; urinary incontinence during
seizures occurs less frequently
R.K./M 40–49 Severe Less seizures; gait improved
H.K./M 18–29 Severe More alert
K.J./M 70–79 Moderate More than 75% reduction of GTCS
G.K./F 60–69 Mild Less dysphoric, more approachable and cooperative; no longer dizzy
J.G./F 30–39 Profound More alert, more cheerful
W.D./M 60–69 Borderline More alert
Slight improvement
E.W./F 50–59 Severe Less seizures; however, verbally aggressive at times.
J.S./F 50–59 Mild Emotionally more stable. No more suicidal ideas. Better cognitive performance
(due to PB withdrawal? LTG was also added.) More seizures, however.
D.S./M 40–49 Mild Decrease of seizure frequency
S.R./F 40–49 Severe Somewhat more alert
B.M./F 60–69 Moderate Less seizures.
H.L./M 30–39 Severe More alert, improved well-being despite increase in seizure number
K.K./M 60–69 Severe Improved general state
H.K./M 60–69 Severe Emotionally more balanced, more approachable.
I.H./F 60–69 Mild Less auras (GTCS unchanged)
B.H./F 60–69 Severe More alert and active, more interested, less dysphoric
S.E./M 30–39 Moderate More than 75% seizure reduction (secondary to dosage increase of concomitant medication?)
K.F./F 70–79 Moderate More than 50% seizure reduction (however, sporadic GTCS)
F: female; M: male; GTCS: generalised tonic–clonic seizure.
Table 9
Temporary problems (33 patients)
Patient initials/sex Age group Intellectual
disability
Problem
O.L./M 18–29 Mild Withdrawal seizures during and after tapering. More aggressive (due to PB reduction? LTG had also
been added)
B.H./F 60–69 Mild Withdrawal seizures (two GTCS in one day) 30 days after PB was stopped
M.S./M 50–59 Profound Withdrawal seizures (psychomotor seizures) during PB reduction
W.R./M 70–79 Mild Withdrawal seizure after PB was stopped. Temporary CBZ toxicity.
K.K./M 60–69 Severe Slight increase in GTCS during tapering.
M.K./M 30–39 Severe Marked increase in GTCS when PB was reduced to 75 mg/d. Tapering was stopped and
only continued after dosage of concomitant VPA had been doubled. Increased tremor.
C.H./F 30–39 Borderline Two seizures in one day, patient demanded to stop PB reduction. Tapering could only
be continued when TPM had been added.
F.K./M 40–49 Mild Temporary LTG toxicity! dose reduction
J.G./F 30–39 Profound Temporary increase of chronic pain after PB was stopped
R.P./M 50–59 Moderate Temporary ESM toxicity! dose reduction
K.J./M 70–79 Moderate Strained and verbally aggressive during PB reduction (!dosage of melperon increased);
more nocturnal seizures (!dosage of concomitant PHT increased)
B.M./F 60–69 Moderate Slightly more seizures during PB reduction.
M.K./F 40–49 Moderate Several withdrawal seizures.
W.R./M 50–59 Severe Seizure relapse during PB reduction (at 50 mg/d). VPA was added. A Parkinson-like clinical
picture developed which was ﬁrst attributed to VPA but did neither resolve after changing from
VPA to OCBZ nor after returning to the original dose of PB. Severe osteoporosis with several
vertebral body fractures was ﬁnally detected, and PB tapering could be continued.
A.P./M 60–69 Severe Seizure relapse during PB reduction (at 25 mg/d). Further reduction was postponed. Developed then
hour-long states including restless walking, confusion, ‘‘wild’’ gazing, and gaze deviation difﬁcult to
differentiate as of epileptic, psychotic or other nature.
J.S./F 50–59 Mild Prolonged psychomotor seizures.
W.S./M 30–39 Moderate One day cluster of withdrawal seizures 4 weeks after PB was stopped.
J.G./M 50–59 Moderate Atypical psychomotor seizure after withdrawal
H.K./M 18–29 Severe More aggressive (pinching) shortly after PB was stopped.
C.S./F 30–39 Moderate LTG toxicity after PB was stopped
S.E./M 30–39 Moderate Cluster of GTCS after reducing PRM to 187,5 mg/d.
K.R./M 40–49 Severe GTCS with subsequent non-convulsive status epilepticus requiring two dosages of rescue
medication during PB reduction (at 25 mg/d). Unexpected bursts of aggression (probably due to
PB withdrawal while other causes could not be excluded).
K.G./F 60–69 Mild Generalised tonic–clonic seizure status during PB reduction (at 15 mg/d)
J.K./F 18–29 Severe Seizure increase after reduction steps, impossible to differentiate if epileptic or psychogenic
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Table 9 (Continued )
Patient initials/sex Age group Intellectual
disability
Problem
J.L./M 40–49 Severe Clusters of seizures during (at 15 mg/d) and after PB reduction, requiring temporary additional
medication (clobazam, acetazolamid)
K.M./M 60–69 Severe An unclear clinical picture including somnolence and collapse developed approx. 10 weeks after
discontinuation (prolonged seizure? AED intoxication? Cerebro-vascular problem?), which could
not completely clariﬁed despite hospital admission; the patient recovered completely within days
H.L./M 40–49 Profound Agitation and sleep disorder during PB reduction.
H.K./M 60–69 Severe Slight seizure increase during PB reduction; LTG toxicity after PB was stopped
L.L./F 60–69 Moderate Slight increase in seizure number after PB was stopped
H.S./M 50–59 Mild A seizure-related fall led to marked contusions requiring hospital admission shortly after PB was stopped
S.P./M 50–59 Mild Prolonged GTCS requiring emergency hospital admission during PB reduction; three GTCS in one day
(which would not happen otherwise) after PB was stopped
J.V./M 30–39 Borderline Cluster of seizures during PB reduction, PB temporarily re-increased, but later successfully discontinued
S.H./M 60–69 Moderate An unclear clinical picture developed during PB reduction (at 125 mg/d) including cognitive loss,
psychotic symptoms (!risperidone introduced), dizziness, unsteady gait (possibly due to PB reduction
but OCBZ toxicity and hyponatremia had also to be considered)
F: female; M: male; GTCS: generalised tonic–clonic seizure.
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are likely to reﬂect changes which are relevant for daily
functioning and for the patients’ well-being.
In several aspects, this work is based upon a very individualised
approach. Decisions like the selection of patients required
thorough consideration of different reasons pro and contra
tapering. These reasons have to be weighted for the individual
patient. Therefore, they could not be made in a standardized way
but rather depended on the expert clinicians’ careful judgement. A
more standardized approach, although desirable from a scientiﬁc
point of view, was also prevented by ethical and legal concerns.
Similar considerations apply for the determination of the reduction
rate. Furthermore, as any treatment has to be negotiated with
patients, carers and legal representatives, their courage or
fearfulness inevitably inﬂuenced the reduction rate. As for the
moment to interrupt the tapering in case of problems arising, the
clinical situations were too manifold to allow schematic decisionsTable 10
Deteriorated patients (N = 12)
Patient initials/sex Age group Intellectual disability Details of deterioration
H.W./M 50–59 Moderate 3–4 GTCS per month com
H.L./M 40–49 Profound Marked seizure increase
F.S./M 18–29 Borderline During PB reduction clus
a marked increase of seiz
AED (LTG)! admission t
from external apartment
helmet. Cognitive abilitie
(9 months after stopping
H.S./M 50–59 Mild More seizures; more phy
C.H./F 30–39 Borderline Paranoid psychosis; had
discontinued (felt threate
increase of incontinence
G.D./M 50–59 Severe Relapse of a focal seizure
stopped, requiring a med
during PB tapering, not c
M.S./M 30–39 Moderate Seizure increase! VPA a
suspected but not conﬁrm
drowning accident (aspir
D.A./M 40–49 Moderate Seizure increase during P
CBZ was then replaced w
M.T./F 60–69 Severe Seizure relapse during PB
dosages not tolerated. CB
in hospital, ﬁnally recove
but severe, requiring resc
W.S./M 30–39 Moderate Slight seizure increase, se
More agile and lively, bu
J.L./M 40–49 Severe Total number of seizures
(absence seizures?), often
D.F./F 40–49 Severe Relapse of GTCS (althoug
F: female; M: male; GTCS: generalised tonic–clonic seizure.(e.g., interruption at 50% seizure increase), as is shown in Table 11
(tapering failed) as well as in Tables 9 and 10 (tapering continued
despite problems during and after tapering).
After a careful clinical assessment of 191 patients on barbiturate
therapy it seemed sensible to refrain from a tapering attempt for
approximately one-half of the patients. The maintenance group
includesmore patients in the older age groups (Table 1); this was to
be expected as older age had been a reason against tapering. More
female patients remained on a barbiturate while clearly more men
were in the withdrawal group (Table 1); we are not aware of any
obvious medical reasons for this imbalance. The main reason to
maintain patients on PB/PRMwas seizure freedom.Nevertheless, 13
seizure free patients entered the tapering trial (Table 1, columns
withdrawal group and tapering failed group). The most prevalent
reason to include these patients despite seizure freedom was very
long duration of seizure control (decades) and, based upon that, the
assumption of a low relapse risk. The results have conﬁrmed thatpared to 1–5 per year before PB was withdrawn
ters of seizures but also long intervals occurred. After complete PB withdrawal:
ure activity which could not be stopped despite higher dosages of concomitant
o hospital. After 3 months in hospital without improvement he had to move
back into the residence (loss of independence). Needed a leather protective
s and daily life capabilities were reduced compared to status quo ante
PB, after another unsuccessful AED trial, PB was re-introduced).
sically aggressive.
been symptom free for years; delusional thinking 3 months after PB was
ned and extorted, vampires, poison arrows come through the telephone);
(urine and stool; causally related to PB withdrawal?)
during PB reduction (50 mg). Three more seizures 5–6 months after PB was
ication change. Restlessness and severe exacerbation of sleep disturbance
ompletely resolved beyond the withdrawal period.
dded. More aggressive, cognitively worse: VPA-induced encephalopathy
ed. Seizures still more severe, more frequent generalisation. A severe
ation, intensive care; full recovery) happened in this context.
B reduction (on 50 mg/d). VPA was added, leading to an increase in CBZ-epoxide.
ith OCBZ. A lasting seizure increase after complete PB withdrawal.
reduction. Concomitant medication (ﬁrst CBZ, then VPA) increased but higher
Z replaced with OCBZ, not either tolerated. General condition reduced, long stay
red but seizure control not regained. Months after PB withdrawal seizures rare
ue medication; needs a whole day to recover.
rial seizures 2–3 times a month, requires rescue medication at occasions.
t gets involved in conﬂicts more frequently.
decreased but more GTCS. Often sleepy and absent-minded
in a bad mood, grumbles a lot.
h infrequent) after long years of seizure control
Table 11
Tapering trial failed (N = 13)
Patient initials/sex Age group Intellectual
disability
Reasons why tapering trial had to be aborted
R.K./F 50–59 Mild GTCS (usually only 1/year) with severe postictal psychosis during PB reduction (at 60 mg); patient demanded
higher dose of PB; at 90 mg PB: patient content having only rare auras
R.F./F 40–49 Moderate Developed side effects from AED which was to replace PB; PB had to be re-introduced
D.H./M 30–39 Moderate Seizure free on PB/CBZ during the year before tapering PB; when PB was reduced to 75 mg/d, a number of
seizures happened; patient asked to reverse reduction
K.K./M 18–29 Severe Usually 1–3 GTCS/month; after reduction to 75 mg/d PB, approx. 5 GTCS/month, temporarily CLB added; on
further reduction to 60 mg/d PB: seizure increase impossible to cover by CLB; back to 100 PB: improvement
R.H./M 50–59 Severe Seizure free; several severe GTCS when PB was reduced to 15 mg/d
H.B./M 60–69 None Patient complained about clusters of unpleasant auras after PB reduction and insisted on his previous dosage
U.D./M 40–49 Severe Severe GTCS after PB reduction (CBZ added), emergency hospital admission; nocturnal seizures were
suspected; exacerbation of challenging behaviour (in the context of his autistic disorder)
T.J./M 30–39 Borderline Several falls caused by increase of GTCS, leading to a nasal bone fracture and to a mandibular fracture
C.T./M 60–69 Severe Seizure relapse after 40 years of seizure control (PB monotherapy; an attempt to discontinue
antiepileptic therapy)
S.B./F 30–39 Mild Severe increase of myoclonic seizures, often in clusters, leading to instable gait, additional ‘‘medication at
request’’ frequently needed, which led to sedation
M.G./M 18–29 Moderate Myoclonic seizures much more frequent and intense, risk of falls, not able to walk alone anymore
W.L./M 50–59 Mild Seizure led to ﬁbula fracture; after further reduction: severe seizure increase
M.W./M 30–39 Moderate Seizure free during the year before tapering PB; seizure increase
F: female; M: male; GTCS: generalised tonic–clonic seizure.
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to learn the lesson that long-term seizure control is no protection
against relapses.
In our organisation most doctors and carers have been familiar
with the patients for years. Nevertheless, in more than half of the
patients it was impossible to know whether or not they suffered
from cognitive or psychological side effects before the tapering
(Table 5). This difﬁculty is obviously inherent to any longstanding
treatment with potentially sedating medications in persons with
intellectual disability. Unlike in persons with average intellectual
capacities, it can be impossible to discern whether a certain deﬁcit
has to be attributed to the person’s handicap itself or to the drug
prescribed. In such cases, the issue of adverse effects on cognition,
attention, mood etc. can only be clariﬁed through tapering the
medication in question—unless the effects are irreversible. In this
report, unexpectedly, only one out of four patients improved
cognitively/psychologically after PB was withdrawn (Table 6),
while 61% remained unchanged. A possible explanation could be
that patients on long-term therapy might have developed
tolerance against adverse effects. It cannot be excluded, on the
other hand, that some adverse effects had become irreversible
during decade-long treatment. Moreover, it can be assumed that in
patients who had more apparent cognitive impairment caused by
PB or PRM, these drugs had already been withdrawn in an early
stage of treatment. The types of change most frequently observed
were improved alertness and better mood. Unfortunately, a small
number of patients worsened cognitively. In 2 of these 5 patients,
among them the one who worsened clearly (F.S. in Table 10), this
happened in the context of seizure increase.
Tapering was carried out carefully and slowly (mean duration
more than a year), and adaptations of the designed reduction
pattern were made whenever seizure exacerbations impended.
Nonetheless, nearly half of the patients (45.8%) had temporary
problems during the tapering (Table 9). These problems included
not only withdrawal seizures, a well-known phenomenon with
barbiturates, but also behavioural changes, toxicity caused by drug
interaction and, mainly in more severely handicapped multi-
morbid patients, unclear (possibly multifactorial) and difﬁcult-to-
manage clinical situations which were triggered by the tapering
procedure (Table 9). Altogether, tapering of PB after long lasting
therapy, carried out in the setting of residential homes, tended to
be tedious and protracted. Since barbiturates have pharmacoki-netic interactions with numerous (antiepileptic and other) drugs, a
careful monitoring of concomitant medications during the
tapering is mandatory. In our trial, the most typical situation
was an increase in serum levels due to omission of PB-related
enzyme induction. In these cases, clinicians had to decide whether
to reduce the dosage of that respective AED. Even though these
decisions could not be made in a formally standardized way, the
following considerationsweremade routinely: Adverse effects and
also a lack of beneﬁt from the increased serum levels were reasons
for dose reduction, while improved seizure control and lack of side
effects were taken as reasons in favour of keeping the serum
concentration increased.
Despite careful patient selection, we saw as many failures and
deteriorations as patients who beneﬁted from the tapering. Tables
10 and 11 illustrate the broad spectrum of deteriorations which by
far exceeded an increase in the pure number of seizures but also
included medical and psychiatric complications (whether related
to withdrawal symptoms or not) as well as social sequelae. The
elimination of sedation, although generally desirable, could have
contributed to the exacerbation of aggression or behavioural
disorder in some cases. Especially patients with well-controlled
seizures were at high risk for relapse seizures while the chance of
positive effects was low. Fortunately, only a minority of the
patients suffered a lasting seizure increase. This was mainly
because the tapering procedure was stopped when temporary
problems could not be solved. Another important risk factor
(nearly fourfold risk) was a history of an attempt to withdraw
barbiturate medication. With these results, our conclusion is to
except patients with well-controlled seizures and patients who
had earlier withdrawal attempts from future efforts to reduce
barbiturate medication.
In contrast, a high seizure frequency was associated with good
outcome. Onemight assume that this could be due to regression to
the mean. Patients with high seizure frequency might have
improved in the context of normal ﬂuctuations of their seizure
frequency rather than dependent on medication change. However,
we used exceptionally long spaces of time in this work. The seizure
frequency before tapering was determined over a period of 1 year,
the tapering procedure again averaged more than a year, and the
post-evaluation period lasted 4 months. Spontaneous ﬂuctuations
of seizure numbers, on the contrary, usually occur rather in terms
of months than of years.
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selection, old age was rather an argument against tapering. By
doing so we had mainly the propensity of senior persons to bone
fractures and other medical complications in mind. Our results
indicate, however, that old age per se is not a contraindication for
barbiturate withdrawal.
Remarkably, no variable related to the barbiturate medication
itself like duration of therapy, dosage, serum concentration,
reduction rate was associated with outcome. Likewise, no
diagnostic parameter like epilepsy syndrome or degree of
intellectual disability was related to outcome.
We must conclude that we did succeed in reducing consider-
ably the number of barbiturate medications in our resident
population, but that the principal aim of the project, to relieve
patients from assumed barbiturate side effects, has been achieved
only in one out of four patients. The multitude of problems and
complications experienced is a reminder that the decision to taper
barbiturate medication after long-term treatment should be made
prudently.
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